Corcept Therapeutics(CORT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CORT Corcept Therapeutics

Pre-Mkt 06-02 08:15:26 EDT

70.44

+0.95

+1.37%

盘前70.43

-0.01-0.01%

08:06 EDT

High71.12	Low68.25	Vol1.10M
Open69.29	D1 Closing69.49	Amplitude4.12%
Mkt Cap7.56B	Tradable Cap6.12B	Total Shares107.36M
T/O76.94M	T/O Rate1.26%	Tradable Shares86.88M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CORT","market":"US","secType":"STK","nameCN":"Corcept Therapeutics","latestPrice":70.44,"timestamp":1780344000000,"preClose":69.49,"halted":0,"volume":1097203,"hourTrading":{"tag":"盘前","latestPrice":70.43,"preClose":70.44,"latestTime":"08:06 EDT","volume":435,"amount":30684.24315,"timestamp":1780402012267,"change":-0.01,"changeRate":-0.000142,"amplitude":0.042589},"delay":0,"changeRate":0.013671031803137184,"floatShares":86875270,"shares":107356686,"eps":0.35,"marketStatus":"Pre-Mkt","change":0.95,"latestTime":"06-02 08:15:26 EDT","open":69.29,"high":71.115,"low":68.25,"amount":76935270.89835,"amplitude":0.041229,"askPrice":70.45,"askSize":11,"bidPrice":67.52,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0.35,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1780407000000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1081915200000,"exchange":"NASDAQ","adjPreClose":70.44,"preHourTrading":{"tag":"盘前","latestPrice":70.43,"preClose":70.44,"latestTime":"08:06 EDT","volume":435,"amount":30684.24315,"timestamp":1780402012267,"change":-0.01,"changeRate":-0.000142,"amplitude":0.042589},"postHourTrading":{"tag":"盘后","latestPrice":70,"preClose":70.44,"latestTime":"19:59 EDT","volume":19389,"amount":1365104.628,"timestamp":1780358348981,"change":-0.44,"changeRate":-0.006246,"amplitude":0.006246},"volumeRatio":1.0811886501463759,"optionData":{"bulkOrders":[{"symbol":"CORT","call":true,"expireDate":1787284800000,"strike":"75.0","timestamp":1780326255474,"price":5.3,"volume":2000,"amount":1060000,"type":"+"}]},"impliedVol":0.5256,"impliedVolPercentile":0.368},"requestUrl":"/m/hq/s/CORT","defaultTab":"news","newsList":[{"id":"2640258959","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2640258959","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640258959?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:00","pubTimestamp":1780315223,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Revolution Medicines (RVMD), Corcept Therapeutics (C...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-197?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-197?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RVMD","IE00BFTCPJ56.SGD","LU0566484027.USD","BK4532","CORT","IE00B4R5TH58.HKD","IE00B2B36J28.USD","IE0002141913.USD","LU0320765992.SGD","LU0889565916.HKD","BK4007","LU0109394709.USD","LU1559883803.SGD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","IE0009355771.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639707836","title":"Corcept Chief Accounting & Technology Officer Joseph Douglas Lyon sells 5,000 shares for $325,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2639707836","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639707836?lang=en_us&edition=fundamental","pubTime":"2026-05-30 06:12","pubTimestamp":1780092739,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics Chief Accounting & Technology Officer Joseph Douglas Lyon sold 5,000 common shares on May 27, 2026.Shares were sold at USD 65, leaving him with 6,230 shares beneficially owned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 29, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nNDL4CRM22:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","BK4532","BK4007","LU0566484027.USD","CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639670219","title":"Corcept Endocrinology President Sean Maduck sells USD 4.92 million Corcept Therapeutics shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2639670219","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639670219?lang=en_us&edition=fundamental","pubTime":"2026-05-30 06:04","pubTimestamp":1780092252,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics reported President, Corcept Endocrinology Sean Maduck exercised options to buy 75,000 shares at $8.27 on May 27.Maduck sold 75,000 shares the same day at weighted-average prices of $65.37 and $66.16.He ended the day with 8,977 shares of common stock held directly.He also reported 166,986 stock options held directly following the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 29, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nNDL5R7zhq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept Endocrinology President Sean Maduck sells USD 4.92 million Corcept Therapeutics shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4532","LU1559883803.SGD","CORT","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639616988","title":"Corcept Therapeutics holds annual shareholder meeting, backs amended 2024 incentive plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2639616988","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639616988?lang=en_us&edition=fundamental","pubTime":"2026-05-29 04:15","pubTimestamp":1779999323,"startTime":"0","endTime":"0","summary":"Shareholders authorized an amendment to the 2024 Incentive Award Plan, expanding the share pool by 8 million shares; the amended plan took effect May 21.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 28, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL1RkqnT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU0566484027.USD","LU1559883803.SGD","BK4007","CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638667714","title":"Corcept Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2638667714","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638667714?lang=en_us&edition=fundamental","pubTime":"2026-05-28 19:06","pubTimestamp":1779966360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CORT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 28, 2026 07:06 ET (11:06 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638668167","title":"U.S. RESEARCH ROUNDUP-Salesforce, Snowflake, Zscaler","url":"https://stock-news.laohu8.com/highlight/detail?id=2638668167","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638668167?lang=en_us&edition=fundamental","pubTime":"2026-05-28 15:30","pubTimestamp":1779953433,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Salesforce, Snowflake, ZscalerMay 28 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Salesforce, S","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f8e1c482dddadf19d230466ebedcbf23","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nL4N4250MW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRVL","BK4086","LU1620156213.USD","MVLL","LU2125910336.SGD","LU1551013425.SGD","LU2413666426.HKD","CRMG","LU0128526141.USD","CORT","LU0963586101.USD","APGE","ZS","LU1923622291.USD","LU2265009873.SGD","LU0323239441.USD","LU2089985449.USD","OKTA","HPQ","OKTX","LU0642271901.SGD","BK4579","WMS","BK4093","LU1988902786.USD","PHR","SNOU","DEC","OKTG","SNOY","LU0314104364.USD","S","ANF","IE00BLSP4452.SGD","A","P","MRVU","NTNX","LU0943347566.SGD","LU0980610538.SGD","BBWI","LU1923623000.USD","LU2931357623.SGD","SNOW","CRM","IE00BJTD4N35.SGD","ECL","DKS","LU0082616367.USD","CF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638656701","title":"Corcept Therapeutics Inc : Canaccord Genuity Raises Target Price to $135 From $110","url":"https://stock-news.laohu8.com/highlight/detail?id=2638656701","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638656701?lang=en_us&edition=fundamental","pubTime":"2026-05-28 11:13","pubTimestamp":1779937999,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nFWN42413S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4532","LU1559883803.SGD","CORT","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638689119","title":"Corcept Therapeutics to resubmit NDA to U.S. FDA for relacorilant","url":"https://stock-news.laohu8.com/highlight/detail?id=2638689119","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638689119?lang=en_us&edition=fundamental","pubTime":"2026-05-27 22:36","pubTimestamp":1779892603,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics (CORT) announced it will resubmit its New Drug Application, NDA, to the U.S. Food and Drug Administration, FDA, for relacorila...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/corcept-therapeutics-to-resubmit-nda-to-u-s-fda-for-relacorilant-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/corcept-therapeutics-to-resubmit-nda-to-u-s-fda-for-relacorilant-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LU0566484027.USD","CORT","BK4532","LABU","BK4585","BK4588","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638550063","title":"BRIEF-Corcept To Resubmit NDA For Relacorilant As Treatment For Cushing's Syndrome Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2638550063","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638550063?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:18","pubTimestamp":1779884328,"startTime":"0","endTime":"0","summary":"BRIEF-Corcept To Resubmit NDA For Relacorilant As Treatment For Cushing's Syndrome PatientsMay 27 (Reuters) - Corcept Therapeutics Inc CORT.O:TO RESUBMIT ITS NEW DRUG APPLICATION FOR RELACORILANT AS A","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nTUA6DNDFW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU1559883803.SGD","BK4007","CORT","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638479507","title":"Corcept plans to resubmit FDA NDA for relacorilant in Cushing’s syndrome after CRL","url":"https://stock-news.laohu8.com/highlight/detail?id=2638479507","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638479507?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:01","pubTimestamp":1779883313,"startTime":"0","endTime":"0","summary":"Corcept plans to resubmit its NDA to the FDA for relacorilant to treat Cushing’s syndrome.The FDA indicated a PDUFA action date is expected six months from the resubmission.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via Business Wire  on May 27, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL5MZqdm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CORT","BK4007","BK4532","LU0566484027.USD","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638794507","title":"Corcept Therapeutics Inc - FDA Expects Pdufa Date Six Months After Nda Resubmission for Relacorilant","url":"https://stock-news.laohu8.com/highlight/detail?id=2638794507","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638794507?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:00","pubTimestamp":1779883201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nTUA6DNDFW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1559883803.SGD","BK4532","LU0566484027.USD","CORT","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638079595","title":"Corcept to Resubmit Its New Drug Application for Relacorilant as a Treatment for Patients With Cushing’s Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2638079595","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638079595?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:00","pubTimestamp":1779883201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nTUA6DNDFW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4532","LU0566484027.USD","CORT","BK4007","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636163050","title":"Does Corcept Therapeutics' (CORT) UBS Upgrade and Insider Gifting Reframe Its Oncology Ambitions?","url":"https://stock-news.laohu8.com/highlight/detail?id=2636163050","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636163050?lang=en_us&edition=fundamental","pubTime":"2026-05-18 01:43","pubTimestamp":1779039787,"startTime":"0","endTime":"0","summary":"Earlier this week, UBS Group upgraded Corcept Therapeutics following increased confidence in Lifyoril, its investigational ovarian cancer therapy, while a senior executive reported bona fide gifts of company shares to family accounts. \nThis combination of heightened optimism around an additional oncology asset and insider estate planning activity offers a fresh lens on Corcept’s evolving profile. \nWe’ll now examine how UBS’s increased confidence in Lifyoril’s regulatory outlook may influence...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/does-corcept-therapeutics-cort-ubs-upgrade-and-insider-gifti","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/does-corcept-therapeutics-cort-ubs-upgrade-and-insider-gifti","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635320027","title":"Corcept Therapeutics Shares Rise After UBS Upgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2635320027","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635320027?lang=en_us&edition=fundamental","pubTime":"2026-05-14 02:33","pubTimestamp":1778697224,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics  shares rose 11.6% in Wednesday trading after UBS Securities upgraded the stock to buy from neutral and adjusted its price target to $72 per share from $44.Trading volume stood at over 1.2 million shares compared with a daily average of about 1.7 million.Price: 57.11, Change: +5.95, Percent Change: +11.62","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635383247","title":"Corcept Therapeutics Inc : UBS Raises to Buy From Neutral","url":"https://stock-news.laohu8.com/highlight/detail?id=2635383247","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635383247?lang=en_us&edition=fundamental","pubTime":"2026-05-13 21:49","pubTimestamp":1778680176,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nAZN4SVXVD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CORT","BK4532","LU1559883803.SGD","BK4007","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635780054","title":"Corcept Therapeutics upgraded to Buy from Neutral at UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2635780054","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635780054?lang=en_us&edition=fundamental","pubTime":"2026-05-13 21:38","pubTimestamp":1778679516,"startTime":"0","endTime":"0","summary":"UBS upgraded Corcept Therapeutics (CORT) to Buy from Neutral with a price target of $72, up from $44. The recent approval of Lifyorli in ovarian ca...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/corcept-therapeutics-upgraded-to-buy-from-neutral-at-ubs-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/corcept-therapeutics-upgraded-to-buy-from-neutral-at-ubs-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635787338","title":"Corcept Therapeutics Raised to Buy From Neutral by UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2635787338","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635787338?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:51","pubTimestamp":1778676660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CORT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 13, 2026 08:51 ET (12:51 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635178789","title":"UBS Upgrades Corcept Therapeutics to Buy From Neutral, Adjusts Price Target to $72 From $44","url":"https://stock-news.laohu8.com/highlight/detail?id=2635178789","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635178789?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:28","pubTimestamp":1778671723,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics (CORT) has an average rating of overweight and mean price target of $79.25, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fr","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633924535","title":"Corcept CEO Joseph Belanoff disposes 40,000 shares worth $2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633924535","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633924535?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:37","pubTimestamp":1778013455,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics CEO Joseph K. Belanoff sold 40,000 common shares on May 1, 2026.Sale priced at USD 50.1 per share on a weighted-average basis.Holdings fell to 2,878,326 shares, held indirectly via Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 05, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDLfsYNP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept CEO Joseph Belanoff disposes 40,000 shares worth $2 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0566484027.USD","LU1559883803.SGD","BK4532","BK4007","CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633603609","title":"Corcept Therapeutics Signals Big Growth After Key Wins","url":"https://stock-news.laohu8.com/highlight/detail?id=2633603609","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633603609?lang=en_us&edition=fundamental","pubTime":"2026-05-05 08:20","pubTimestamp":1777940449,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics (($CORT)) has held its Q1 earnings call. Read on for the main highlights of the call. Corcept Therapeutics’ latest earnings ca...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/corcept-therapeutics-signals-big-growth-after-key-wins?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/corcept-therapeutics-signals-big-growth-after-key-wins?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4532","LU1559883803.SGD","CORT","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.corcept.com","stockEarnings":[{"period":"1week","weight":0.1697},{"period":"1month","weight":0.3699},{"period":"3month","weight":0.9966},{"period":"6month","weight":-0.1581},{"period":"1year","weight":-0.0918},{"period":"ytd","weight":1.0241}],"compareEarnings":[{"period":"1week","weight":0.0173},{"period":"1month","weight":0.0526},{"period":"3month","weight":0.115},{"period":"6month","weight":0.1092},{"period":"1year","weight":0.287},{"period":"ytd","weight":0.1124}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.022337},{"month":2,"riseRate":0.409091,"avgChangeRate":0.008661},{"month":3,"riseRate":0.772727,"avgChangeRate":0.140734},{"month":4,"riseRate":0.545455,"avgChangeRate":0.005665},{"month":5,"riseRate":0.521739,"avgChangeRate":0.028192},{"month":6,"riseRate":0.478261,"avgChangeRate":0.037993},{"month":7,"riseRate":0.454545,"avgChangeRate":-0.006529},{"month":8,"riseRate":0.409091,"avgChangeRate":-0.006283},{"month":9,"riseRate":0.454545,"avgChangeRate":0.062175},{"month":10,"riseRate":0.5,"avgChangeRate":-0.005789},{"month":11,"riseRate":0.5,"avgChangeRate":0.018834},{"month":12,"riseRate":0.409091,"avgChangeRate":0.027449}],"exchange":"NASDAQ","name":"Corcept Therapeutics","nameEN":"Corcept Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.4","shortVersion":"4.42.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Corcept Therapeutics(CORT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Corcept Therapeutics(CORT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Corcept Therapeutics,CORT,Corcept Therapeutics股票,Corcept Therapeutics股票老虎,Corcept Therapeutics股票老虎国际,Corcept Therapeutics行情,Corcept Therapeutics股票行情,Corcept Therapeutics股价,Corcept Therapeutics股市,Corcept Therapeutics股票价格,Corcept Therapeutics股票交易,Corcept Therapeutics股票购买,Corcept Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Corcept Therapeutics(CORT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Corcept Therapeutics(CORT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}